We read a lot of real life stories of myeloma patients and what I understood is that its most important for the myeloma diagnosis to take place at an early stage. Unfortunately, it seems like it usually takes a long time to diagnose myeloma, since the symptoms can appear to be temporary...
1. What is myeloma? Myeloma is a hematologic malignancy comprising about 1% of all cancers. It consists of an excess of clonally expanded cytogenetically heterogeneous bone marrow-derived plasma cells with two cardinal features: a monoclonal immunoglobulin (the paraprotein or M-protein) and/or assoc...
iii) What about Human or Non-B Cell mAbs? The preceding description is of the production of murine monoclonal antibodies in a mouse system. In cases where the goal is to use mAbs in clinical treatment, a problem arises because, not unexpectedly, the introduction of mouse mAbs into humans pr...
Is it osteoporosis or multiple myeloma?Pate, Deborah
M protein is an abnormal protein caused by plasma cells. See why Myeloma protein might show up in your blood and what kinds of conditions it might be a sign of.
PB2189 FREE LIGHT CHAINS IN MULTIPLE MYELOMA: IS IT TIME TO EXTEND THEIR APPLICATION?doi:10.1097/01.HS9.0000567236.65953.60Markovic, U.Leotta, V.Giubbolini, R.Romano, A.Del Fabro, V.Di Raimondo, F.Conticello, C.HemaSphere
Multiple myeloma is a type of blood cancer. Read about the basics of the disease, including what causes it, how it makes you feel, stages of the disease, and other important facts you need to know.
What are some unanswered questions about this drug? I think the question is going to be, how do you partner [BCMA-targeting agents] with other drugs? Those trials are being done now, combining it with pomalidomide [Pomalyst], with bortezomib [Velcade], with lenalidomide [Revlimid]. How you...
As more information is gathered on patients’ genomic abnormalities, there will be a better understanding of what high-risk myeloma is comprised of and how to treat it [75]. Hopefully, future clinical trials will adopt comprehensive sequencing strategies to fully understand how the genomics of the...
4. Now What? Precision medicine intends to provide the right treatment to the right patient at the right dose, at the right time. ImmunoPET perfectly fits in this strategy. It has previously demonstrated its usefulness in precisely mapping lesion profiles at the molecular level, identifying the ...